Expect Tazobactum approval by June 07: Orchid Chem
16 August 2006
K Raghavendra Rao, managing director, Orchid Chemicals and Pharma, expects the approval for Tazobactum sometime by June 2007, while the product patent is expiring in Europe for this product in July 2007. "So we expect to be in the market on day one with this product," he says. Rao also expects very little competition because of the complexity of manufacturing Tazabactum. He further says that the product has got around $200 million-market originator in Western Europe. "So with very limited generic players, the pricing and profitability should be extremely good for this product from Europe," he says.CNBC-TV18 shares with domain-b its exclusive interview with Rao: Tazobactum is the product in focus now. When are you likely to receive this European marketing approval? So we expect the approval sometime by June 2007 and the product patent is expiring in Europe for this product in July 2007. So we expect to be in the market on day one with this product. |